



Biotech Daily

Thursday September 17, 2020

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: CYCLOPHARM UP 35%; ACTINOGEN DOWN 10%**
- * **MEDADVISOR LAUNCHES ELECTRONIC PRESCRIPTIONS**
- * **EMERALD, MT SINAI PARTNER FOR OPENLY REMOTE MONITOR**
- * **AVECHO RECEIVES \$615k R&D TAX INCENTIVE**
- * **FIL TAKES 7% OF STARPHARMA**
- * **EYE CO APPOINTS ALISON COUTTS DIRECTOR**

MARKET REPORT

The Australian stock market fell 1.22 percent on Thursday September 17, 2020, with the ASX200 down 72.9 points to 5,883.2 points.

Six of the Biotech Daily Top 40 stocks were up, 26 fell, and eight traded unchanged. All three Big Caps fell.

Cyclopharm was the best for the second day in a row, on Tuesday's positive pivotal trial results, up 67 cents or 34.4 percent to \$2.62, with 348,170 shares traded.

Antisense climbed 15 percent on no news; Patrys improved 7.1 percent; Pharmaxis was up 3.7 percent; Volpara rose 1.15 percent; with Genetic Signatures up 0.5 percent.

Actinogen led the falls, down 0.3 cents or 10 percent to 2.7 cents, with 3.9 million shares traded.

Proteomics lost 8.7 percent; Dimerix and Oncosil were down more than seven percent; Alterity shed 6.25 percent; Optiscan and Pro Medicus fell more than four percent; Next Science and Polynovo were down more than three percent; Clinuvel, Impedimed, Imugene, Mesoblast, Opthea, Orthocell, Prescient and Telix shed more than two percent; Cochlear, Compumedics, CSL, Cynata, Nanosonics, Paradigm, Resmed, Starpharma and Universal Biosensors were down more than one percent; with Avita, Medical Developments and Neuren down by less than one percent.

MEDADVISOR

Medadvisor says it has launched its electronic-prescribing software in Australia to facilitate electronic prescriptions for general practitioners, pharmacies and patients.

Medadvisor said its electronic-prescribing, or e-prescribing, was accessible through a “private and secure” smartphone application to help patients keep track of and organize all their electronic prescriptions.

The company said its smartphone application would provide revenue streams including text message reminders, health programs and transactions made through the software, such as paying for general practitioner services.

Medadvisor chief executive officer Robert Read said that “with the rise of tele-health and digital consults during this Covid-19 pandemic and the changes to prescribing temporarily allowed by the Government, prescribers have needed to send digital images of scripts directly to pharmacies via fax or email, which adds significant administrative burden for both prescribers and pharmacies, and poses the risk of prescribers channelling patients to specific pharmacies”.

“The introduction of [electronic] prescriptions will solve these issues and put the control back in the patient’s hands,” Mr Read said.

Medadvisor said the rollout of the software would begin immediately in Victoria and continue throughout other Australian states “later this month”.

Medadvisor was up 2.5 cents or 5.95 percent to 44.5 cents.

EMERALD CLINICS

Emerald says it has an agreement with New York’s Mt Sinai Hospital for its Openly smartphone application for remote health monitoring.

Emerald said the Mt Sinai precision recovery team was currently monitoring coronavirus cases and would provide remote monitoring and consulting services to support the development the Openly service.

The company said it would provide access to the Openly application to Mt Sinai as well as an unspecified payment for Mt Sinai to review any alerts generated by the Openly platform when certain survey responses or other health information were entered by the user.

Emerald chief executive officer Michael Winlo said the agreement allowed the company to “benefit from the real-world experiences and expertise of the precision recovery team which will help enhance the capabilities of the Openly technology as well as the health screening services our clinical team can deliver”.

Emerald fell 0.2 cents or 2.3 percent to 8.6 cents.

AVECHO (FORMERLY PHOSPHAGENICS)

Avecho says it has received \$615,000 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Avecho said the rebate related to research and development expenditure for the year to June 30, 2019.

Avecho was up 0.05 cents or 6.7 percent to 0.8 cents.

STARPHARMA HOLDINGS

Fidelity International Limited (FIL) says it has increased its substantial shareholding in Starpharma from 22,413,859 shares (6.02%) to 26,141,471 shares (7.02%).

The Sydney and Hong Kong-based FIL said that between August 28 and September 14, 2020 it bought 3,727,612 shares at prices ranging between \$1.4221 and \$1.6987 a share. Starpharma fell three cents or 1.8 percent to \$1.64 with one million shares traded.

EYE CO PTY LTD

Eye Co said it has appointed Alison Coutts as a non-executive director, effective from September 16, 2020.

Eye Co said Ms Coutts was the current executive chair of Memphasys, had previously worked for EG Capital, Boston Consulting Group and Egon Zehnder International and was the former chair of the Commonwealth Scientific and Industrial Research Organization's health sector advisory council.

The company said Ms Coutts held a Bachelor of Chemical Engineering from the University of Melbourne and a Master of Business Administration from the University of Melbourne Business School.

Eye Co is a private company.